Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

ERBB2 epitope peptide bound to E9 antibody

A technology of antibody complexes and antigens, applied in the field of biomedicine, can solve problems such as limiting the scope of application

Active Publication Date: 2021-03-16
程联胜
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, with its widespread use, drug resistance also appears, limiting its application range
Moreover, the domestic price of 440mg Trastuzumab exceeds RMB 25,000, and the cost of each course of treatment exceeds RMB 200,000

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • ERBB2 epitope peptide bound to E9 antibody
  • ERBB2 epitope peptide bound to E9 antibody
  • ERBB2 epitope peptide bound to E9 antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Example 1, Analysis of antigenic epitopes in the scFv-ECD complex

[0082] This example analyzes the scFv of the E9 antibody (that is, the single-chain antibody formed by connecting the light chain variable region and the heavy chain variable region of E9, referred to as E9 scFv) and the ECD region of the ErbB2 protein (ErbB2 ECD, the sequence in the sequence listing 6) The formed scFv-ECD complex determined the E9 antibody and ErbB2 ECD binding region and the corresponding epitope.

[0083] 1. Preparation of scFv-ECD complex

[0084] Both E9 scFv and ErbB2 ECD express an Fc fragment of IgG1 in series at their carboxy-terminal by genetic engineering methods, and add an enterokinase restriction site before the Fc fragments of the two (the resulting fusion proteins are respectively designated as E9 scFv- Fc and ErbB2 ECD-Fc) were prepared. The fusion proteins were all secreted and expressed by the eukaryotic expression system CHO-K1 cell line, purified and mixed at a mo...

Embodiment 2

[0157] Example 2, E9 antibody has the effect of inhibiting tumor cell growth

[0158] The test cells are: OE19 (Nanjing Kebo Biotechnology Co., Ltd.)

[0159] The antibodies or antibody combinations to be tested are: E9, Pertuzumab, Herceptin, Pertuzumab+Herceptin (mass ratio 1:1), E9+Herceptin (mass ratio 1:1).

[0160] Specific steps are as follows:

[0161] 1. Trypsinize the cells in logarithmic growth phase, add culture medium to make cell suspension;

[0162] 2. 3000-20000ug antibody / 100μl per well, add cells into 96-well plate, and culture for 24hr;

[0163] 3. From the highest concentration, add 100 μl of the test product diluted >9 concentrations by 2-4 times to each well, 3-6 parallel wells for each concentration, and use the medium as the control; the combined drug regimen is two antibodies according to 1: The mass ratio of 1 is mixed with the drug, and the dosage of each antibody is the same as that of the antibody single drug;

[0164] 4. After 72 hours, add 20...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses an ErbB2 antigen epitope peptide bonded with an E9 antibody. The ErbB2 antigen epitope peptide disclosed by the invention is an antigen epitope peptide respectively named as A1and / or B1, wherein A1 contains amino acid residues as follows: Arg at a site 136 of a sequence 6 in a sequence table, Pro at a site 138, Cys at a site 141, Tyr at a site 142 and Asp at a site 144; and B2 contains amino acid residues as follows: Asn at a site 141 of the sequence 6 in the sequence table, Arg at a site 167, Cys at a site 171, His at a site 172 and Glu at a site 186. Compared with abonding region between chA21 and ErbB2, an ErbB2 antibody, antigen epitope peptide bonded with the ErbB2 antibody and antigen epitope have the advantages that the bonding sequences between E9 and ErbB2 are reduced, and the preparation of new ErbB2 antibody is promoted.

Description

technical field [0001] The invention relates to an ErbB2 epitope peptide combined with an E9 antibody in the field of biomedicine. Background technique [0002] ErbB2 belongs to the epidermal growth factor receptor (Epidermal Growth Factor Receptor, EGFR) subfamily (or ErbB family) in the tyrosine protein kinase (Tyr Protein Kinase) family. EGFR takes its name from the first member of the family to be discovered, EGFR, also known as ErbB1 or HER1. There are four members of this family: ErbB1 (EGFR / Her1), ErbB2 (Her2 / Neu / P185), ErbB3 (Her3), ErbB4 (Her4), all of which are typical transmembrane receptor tyrosine kinases ( figure 1 ). The extracellular domain of this type of protein kinase causes its own conformational change after receiving extracellular signal molecules, and through the formation of homodimers or heterodimers, the intracellular parts contact each other and activate their protein kinase functions, and the dimer is completed. Mutual phosphorylation of intrac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/82C07K16/32C12N15/12C12N15/13A61K39/395A61P35/00G01N33/574
CPCA61K2039/505C07K14/82C07K16/32C07K2317/33C07K2317/73C07K2317/92G01N33/57484
Inventor 程联胜刘兢郭龚睿赵群
Owner 程联胜
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com